Demographics and clinical neuropathy evaluation in control subjects and diabetic patients
| Control subjects | No neuropathy | Mild | Moderate | Severe | |
|---|---|---|---|---|---|
| n | 15 | 10 | 18 | 15 | 11 |
| Age (years) | 55.0 ± 4.78 | 53.5 ± 3.23 | 58.6 ± 3.07 | 57.5 ± 2.79 | 61.9 ± 1.89 |
| Duration (years) | 0 | 16.7 ± 4.44 | 18.4 ± 2.64 | 25.2 ± 3.28 | 20.4 ± 3.41 |
| A1C (%) | — | 7.16 ± 0.40 | 7.85 ± 0.38 | 8.30 ± 0.41 | 7.88 ± 0.27 |
| Type 1/type 2 | — | 3/7 | 6/12 | 5/10 | 2/9 |
| Sex (male/female)* | 6/9 | 6/4 | 15/3 | 11/4 | 10/1§ |
| SNOL (ms)† | 2.43 ± 0.12 | 2.63 ± 0.14 | 3.03 ± 0.13§ | 3.66 ± 0.48 | 3.03 ± 0.36 |
| SNAP (μV)¶ | 20.25 ± 3.76 | 14.44 ± 2.36 | 5.74 ± 0.79§ | 5.65 ± 1.19§ | 2.65 ± 0.76§ |
| SNCV (m/s)† | 46.52 ± 1.87 | 42.99 ± 1.42 | 41.20 ± 1.28 | 38.19 ± 2.03§ | 35.18 ± 2.14§ |
| PNOL(ms)† | 4.09 ± 0.28 | 4.72 ± 0.31 | 4.62 ± 0.18 | 5.42 ± 0.27§ | 6.41 ± 0.88 |
| PNAP (mV)‡ | 4.27 ± 0.64 | 4.26 ± 0.59 | 2.91 ± 0.43 | 1.54 ± 0.22§ | 1.10 ± 0.75§ |
| PNCV (m/s)‡ | 45.71 ± 0.99 | 44.15 ± 0.79 | 40.82 ± 0.84§ | 36.88 ± 1.41§ | 32.37 ± 2.48§ |
| PNFL (ms)‡ | 47.36 ± 1.58 | 53.26 ± 1.82 | 57.43 ± 1.80§ | 57.07 ± 2.17§ | 63.37 ± 5.73§ |
| TNOL (ms)‡ | 4.76 ± 0.23 | 5.11 ± 0.42 | 5.67 ± 0.22 | 6.89 ± 0.43§ | 8.29 ± 0.62§ |
| TNAP (mV)‡ | 8.70 ± 1.02 | 6.00 ± 0.72 | 4.82 ± 0.57§ | 3.46 ± 0.99§ | 0.83 ± 0.24§ |
| TNCV (m/s)‡ | 45.94 ± 0.98 | 40.24 ± 1.31§ | 38.67 ± 0.87§ | 36.06 ± 0.78§ | 31.18 ± 3.82§ |
| TNFL (ms)‡ | 48.59 ± 1.21 | 55.86 ± 1.95 | 57.73 ± 1.85§ | 58.94 ± 2.16§ | 72.23 ± 4.72§ |
| CDT (percentile)‡ | — | 66.90 ± 8.99 | 74.22 ± 7.12 | 96.67 ± 0.59‖ | 98.00 ± 0.91‖ |
| HP-VAS 0.5 (percentile)* | — | 41.38 ± 8.87 | 34.06 ± 8.49 | 52.20 ± 9.68 | 81.20 ± 11.20¶ |
| HP-VAS 5.0 (percentile)* | — | 46.13 ± 13.19 | 34.67 ± 7.87 | 48.33 ± 9.23 | 75.80 ± 9.40¶ |
| HP-VAS 0.5–5.0 (percentile) | — | 55.00 ± 11.62 | 40.00 ± 7.81 | 52.85 ± 9.19 | 44.17 ± 18.10 |
| DB-HRV (percentile)‡ | — | 82.88 ± 4.97 | 34.00 ± 7.91‖ | 14.00 ± 5.26‖ | 14.38 ± 8.67‖ |
Data are means ± SE for age, duration of diabetes, A1C, and measures of electrophysiology and QSTs in diabetic patients and control subjects. Statistically significant difference using ANOVA:
* P < 0.05;
† P < 0.01;
‡ P < 0.001.
§ Post hoc results significantly different from control subjects.
‖ Post hoc results significantly different from the group with no neuropathy.
¶ Post hoc results significantly different from the group with mild neuropathy.